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Abstract
Background and Aim: Currently, no data on the optimal time point after acute ischemic stroke (IS) at which high-
sensitivity C-reactive protein (hs-CRP) level is most predictive of unfavorable outcome. We tested the hypothesis
that hs-CRP levels during both acute (48 h after IS) and convalescent (21 days after IS) phases are equally
important in predicting 90-day clinical outcome after acute IS. We further evaluated the impact of erythropoietin
(EPO), an anti-inflammatory agent, on level of hs-CRP after acute IS.
Methods: Totally 160 patients were prospectively randomized to receive either EPO therapy (group 1, n = 80)
(5,000 IU each time, subcutaneously) at 48 h and 72 h after acute IS, or placebo (group 2, n = 80). Serum level of
hs-CRP was determined using ELISA at 48 h and on day 21 after IS and once in 60 healthy volunteers.
Results: Serum level of hs-CRP was substantially higher in all patients with IS than in healthy controls at 48 h and
day 21 after IS (all p < 0.001). Levels of hs-CRP did not differ between group 1 and 2 at 48 h and day 21 after IS
(all p > 0.5). Multivariate analysis showed that hs-CRP levels (at 48 h and day 21) were independently predictive of
90-day major adverse neurological event (MANE) (defined as recurrent stroke, NIHSS≥8, or death) (all p < 0.03),
whereas EPO therapy was independently predictive of reduced 90-day MANE (all p < 0.02).
Conclusion: EPO therapy which was independently predictive of freedom from 90-day MANE did not alter the
crucial role of hs-CRP levels measured at 48 h and 21-day in predicting unfavorable clinical outcome after IS.
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Background
Numerous studies have already shown that inflamma-
tion plays a crucial role in the initiation of endothelial
dysfunction, atherosclerosis and plaque formation, pro-
pagation of plaque burden, and finally, rupture of the
vulnerable plaque and acute arterial obstructive
syndrome (AOS) [1-4]. Although a myriad of inflamma-
tory biomarkers have been reported to be useful in pre-
dicting endothelial dysfunction and the likelihood of
AOS, high-sensitivity C-reactive protein (hs-CRP)
remains one of the most extensively studied and widely
accepted inflammatory biomarkers in our daily clinical
practice [4-10].
Indeed, not only is hs-CRP an inflammatory biomar-
ker, but it has also been proved to directly participate in
the inflammatory process contributing to acute AOS
[3,4,7]. Besides, immense clinical observational studies
have demonstrated that serum level of hs-CRP is a use-
ful and powerful inflammatory marker in predicting
future cardiovascular and cerebrovascular events in
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[3,4,7-11].
CRP, an acute-phase reactant, is synthesized and
secreted in the liver 6 h after an acute inflammatory sti-
mulus [12,13] regardless of the etiologies. Both acute
myocardial infarction6 and acute ischemic stroke (IS)
[14,15] promptly induce an ele v a t i o ni nc i r c u l a t o r yh s -
CRP from ischemic tissue damage. The half life of hs-
CRP in circulation is about 24 hours [16]. Since its rela-
tively short half-life implies that its serum level should
return to the baseline level two weeks after an acute
ischemic insult such as acute AOS, researchers usually
focus on the role of hs-CRP level during acute phase
[4,6,14,15] rather than during recovery phase in predict-
ing clinical outcome. On the other hand, whether serum
hs-CRP level during acute or convalescent phase is
more accurate in predicting clinical outcome in patients
after acute IS remains uncertain.
Not only has erythropoietin (EPO) been shown to
enhance erythropoiesis under anemic condition, but it
has also been reported to be anti-apoptotic [17,18], anti-
inflammatory [19,20], and to play a role in the mobiliza-
tion of endothelial progenitor cells (EPCs) to circulation
and angiogenesis [21-23]. Our recent study [24] has
demonstrated that EPO therapy significantly improved
90-day clinical outcome in patients after acute IS. How-
ever, the study [24] did not show the effect of EPO on
the serum level of hs-CRP. Accordingly, this study not
only examined whether serum hs-CRP levels during
acute and convalescent phases play equally important
role in predicting 90-day clinical outcome in patients
after acute IS, but it also investigated the impact of EPO
therapy on serum hs-CRP level.
Materials and methods
Study Design
This study was a sub-study of our recently reported
clinical trial [24] which was approved by the Institu-
tional Review Committee on Human Research at Chang
Gung Memorial Hospital (No 96-1381A) in 2007 and
conducted at Kaohsiung Chang Gung Memorial Hospi-
tal. The clinical trial [24] registration number was
ISRCTN71371114.
Our recently reported clinical trial [24] was prospec-
tive, randomized, and placebo-controlled. The primary
end-point was to examine the safety and efficacy of two
doses of EPO (Epoetin beta, Roche) (5,000 IU each time,
subcutaneous) administered at 48 h and 72 h after acute
IS in reducing 90-day combined endpoint of recurrent
stroke or death, while the secondary end-point was to
assess the serial changes of circulating EPC level in
patients after acute IS [24]. Furthermore, the study [24]
was designed to evaluate the impact of EPO therapy on
the combined adverse neurological event (MANE)
[defined as recurrent stroke, National Institutes of
Health Stroke Scale (NIHSS) ≥ 8, or death] and on the
serum level of hs-CRP after acute IS. Instead of EPO,
the placebo-control subjects received 1 mL of subcuta-
neous normal saline at 48 h and 72 h after acute IS.
Definitions, Sample Size, Inclusion and Exclusion Criteria
Stroke was defined as a sudden onset of loss of global or
focal cerebral function persisting for more than 24
hours [24]. Patients of all ages with acute IS were eligi-
ble. Inclusion criteria according to a previous clinical
trial [22] included a scoring > 2 on the NIHSS (scores
up to 8 indicate moderate neurological status disability)
and a time window of ≤ 48 h from onset of symptoms
to blood sampling (at 48 h after IS) and study drug
administration (time to treatment just after blood sam-
pling). Patients with history of the followings were
excluded from the study: intracranial hemorrhage, sur-
gery or trauma within the preceding 3 months, abnor-
mal liver function, renal insufficiency (serum creatinine
> 1.5 mg/dL), malignancy, febrile disorders, acute or
chronic inflammatory disease at study entry, liver cir-
rhosis, atrial fibrillation, congestive heart failure, contra-
indications for Magnetic Resonance Imaging (MRI)
examination, no evidence of acute IS on MRI study.
Additionally, patient who had history of allergy to
EPO, hematological disorders including myeloprolifera-
tive disorder, leukemia, thrombocythemia, polycythemia,
past history of deep vein thrombosis, abnormal elevation
of hemoglobin (male > 14.5 gm/dL; female > 13.5 gm/
dL), or received thrombolytic therapy upon presentation
were also excluded from this trial.
An estimated sample size of 157 patients was based on
the effective size with an a = 0.05, a power of 80%, a
difference in circulating level of EPCs between the
patients with NIHSS < 12 and NIHSS ≥12 at 48 h after
acute IS of 0.3%, and a standard deviation of 1.0% in
patients with NIHSS < 12 and 0.9% in patients with
NIHSS ≥ 12 at 48 h after acute IS. A 20% rate of proto-
col violations was assumed. The calculation of sample
size for specific objective was based on our recent report
[24].
An overview of the study protocol has been shown in
the clinical trial in details [24]. From October 2008
through March 2010, consecutive patients with acute IS
were enrolled by the responsible neurologists at the
institute. Eighty-three patients constituted the EPO ther-
apy group in the clinical trial [24]. Because three serum
samples were missed, the remaining 80 patients were
enrolled into the present study as group 1. Additionally,
84 patients constituted the placebo control group in the
clinical trial [24]. Also, since four serum samples were
lost, the remaining 80 patients were enrolled into the
current and assigned as group 2.
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were also studied for circulating level of EPCs and
serum level of hs-CRP. Informed consent was obtained
from all study subjects.
Assessment of Neurological Function
Evaluation of severity of neurological impairment in the
patients with stroke was based on the National Institutes
of Health Stroke Scale (NIHSS) [25] during the acute (at
48 h), convalescent (on day 21), and chronic (day 90)
phases of stroke by neurologists blinded to the treat-
ment allocation (i.e. a double-blind study). Moderate
neurological impairment (i.e. neurological sequelae that
requires partial support in daily activities) was defined
as a score of ≥ 8 on NIHSS, a modified criteria reported
previously [24,26]. In addition to NIHSS, assessments
during admission included functional measures, Barthel
Index [27], and modified Rankin Scale score [28].
Imaging Studies
After admission, other imaging examinations included
chest X-ray, routine brain computed tomography,
duplex scanning of the carotid arteries, and routine car-
diac analysis by 12-lead electrocardiogram and
echocardiography.
The criteria for radiological diagnosis of acute IS
included brain computed tomography showing a new find-
ing of low attenuation density in focal or diffuse brain
area, or MRI examination showing area(s) of high intensity
(bright spots) on diffusion weighted image (DWI) MRI as
described in details in our recent report [22].
Blood Sampling and Assessment
Blood samples were obtained at 48 h (acute phase) and
on day 21 (convalescent phase) after IS at 9.00 a.m. for
assessment of the serum level of hs-CRP in IS patients.
Blood samples were also obtained once in control sub-
jects who participated in a health screening program in
our Health Clinic at 9.00 a.m.
Venous blood was obtained from the antecubital vein
into tubes with EDTA. White blood cell (WBC) count,
red blood cell (RBC) count, hemoglobulin level, and bio-
chemical data were acquired at 48 h and on day 21 after
acute IS using standard laboratory methods. After cen-
trifugation, aliquots of the serum samples were stored at
-80
0 C before hs-CRP assay.
Serum hs-CRP level was measured by duplicated
determination with a commercially available ELISA kit
(R & D R&D Systems, Inc. Minneapolis, USA). The
analytical range extended from 5 to 5000 pg/mL. The
intra-individual variability of hs-CRP levels was
assessed in both study patients and control subjects.
The mean intra-assay coefficients of variance were all
less than 4.0%.
Medications
Aspirin was the first choice for patients with acute
stroke in the absence of allergy, intolerance, or a history
of peptic ulcer or upper gastrointestinal tract bleeding
during aspirin therapy. Clopidogrel was used in patients
intolerant to aspirin therapy. Other commonly used
drugs included statins, angiotensin converting enzyme
inhibitors (ACEIs)/angiotensin II type I receptor block-
ers (ARB), diuretics, calcium channel blocking agents,
and beta blockers.
Statistical Analysis
Categorical data were analyzed by Chi-square test or
Fischer’s exact test between two groups. Continuous vari-
ables between two groups were performed using Student
t test. Continuous variables among the three groups were
analyzed by one-way ANOVA followed by multiple com-
parison procedure by Bonferroni correction. The Spear-
man’s Rank test was used to assess the correlations
between quantitative variables without normal distribu-
tion. The receiver operating characteristics (ROC) curve
analysis was utilized to determine which serum hs-CRP
level at 48 h after acute IS was the most powerful predic-
tive of 90-day MANE. Multivariate logistic regression
analysis was utilized for identifying the independent pre-
dictors of prognostic outcomes. Statistical analysis was
performed using SPSS statistical software for Windows
version 13 (SPSS, Inc., Chicago, Ill., USA). A value of p <
0.05 was considered statistically significant.
Results
Baseline Characteristics of Study Patients and Normal
Control Subjects (Table 1)
Table 1 summarizes the baseline characteristics of group
1 (EPO group) and group 2 (placebo group) patients as
well as healthy control subjects. No significant difference
was noted among the three groups in terms of age, gen-
der, and body mass index. Likewise, there was no nota-
ble difference between group 1 and group 2 in coronary
artery disease risk factors and the incidence of previous
and old myocardial infarction. Moreover, laboratory
findings showed that the RBC count, hemoglobin con-
centration, hematocrit, serum levels of total cholesterol,
low-density lipoprotein (LDL) and creatinine did not dif-
fer among the three groups. On the other hand, serum
level of hs-CRP (at 48 h) and WBC count were signifi-
cantly higher, whereas the level of high-density lipopro-
tein was notably lower in groups 1 and 2 than those in
healthy controls. No significant difference in these para-
meters, however, was evident between groups 1 and 2.
Furthermore, both systolic and diastolic blood pressures
were remarkably higher in groups 1 and 2 than in
healthy control subjects, but they were similar between
groups 1 and 2. Also, HbA1C level, incidence of extra-
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not differ between group 1 and group 2.
By day 21, the serum level of hs-CRP also did not dif-
fer between EPO group and placebo group. However,
the hs-CRP level remained significantly higher in both
E P Og r o u pa n dp l a c e b og r o u pc o m p a r e dw i t ht h a ti n
the healthy control group (2.95 ± 4.35 vs. 2.78 ± 2.95 vs.
0.99 ± 1.11, respectively, all p < 0.005).
Comparison of Neurological Status and Clinical Outcome
between Patients with and without EPO Treatment (Table 2)
There were no significant differences in terms of NIHSS,
Barthel Index, and modified Rankin Scale score at 48 h
after acute IS between patients in group 1 and group 2.
Besides, the 90-day NIHSS was also similar between the
two groups. Similarly, the 90-day mortality did not differ
between the two groups. However, the incidence of
recurrent stroke and 90-day NIHSSS ≥ 8 were remark-
ably higher in group 2 than in group 1. Moreover, the
combined major adverse neurological event (MANE)
(defined as NIHSS ≥ 8, recurrent stroke or death on day
90 after acute IS) was notably higher in group 2 than in
group 1.
Univariate and Multivariate Analysis of Predictor for 90-
Day MANE (Tables 3 and 4)
All the variables in Table 1 were utilized for univariate
analysis (Table 3) and the results demonstrated that hs-
Table 1 Comparison of Baseline Characteristics and Laboratory Findings among Three Groups
Variables Group 1
(n = 80)†
Group 2
(n = 80)†
Healthy Control
(n = 60)
P value*
Age (y) (mean ± SD), 63.7 ± 11.2 66.7 ± 11.2 64.1 ± 6.0 0.134
Male, % (n) 65.0% (52) 67.5% (54) 65.0% (39) 0.932
Hypertension, % (n) 65% (52) 75% (60) - 0.168
Diabetes mellitus, % (n) 38.8% (31) 32.5% (26) - 0.409
Current smoking, % (n) 37.5% (30) 27.5% (22) - 0.177
Previous stroke by history, % (n) 25% (20) 21.3% (17) - 0.708
Previous stroke by MRI, % (n) 62.5% (50) 57.5% (46) - 0.628
Old myocardial infarction, % (n) 8.8% (7) 6.3% (5) - 0.781
RBC count (x10
6/uL) 4.75 ± 0.68 4.71 ± 0.65 4.81 ± 0.64 0.561
Hemoglobin (g/dL) 14.0 ± 2.0 14.2 ± 1.7 14.1 ± 1.6 0.963
Hematocrit (%) 41.3 ± 5.8 41.4 ± 6.1 40.9 ± 6.1 0.877
WBC count (x10
3/uL) 7.88 ± 2.41
a 7.83 ± 2.31
a 5.91 ± 1.84
b < 0.001
Total cholesterol level (mg/dL) 185.4 ± 41.0 189.0 ± 39.5 193.3 ± 36.4 0.504
HDL (mg/dL) 44.6 ± 10.9
a 49.2 ± 17.7
a 53.8 ± 14.8
b 0.001
LDL (mg/dL) 115.2 ± 35.8 113.8 ± 36.1 117.2 ± 30.9 0.853
Creatinine (mg/dL) 1.01 ± 0.39 1.02 ± 0.43 1.01 ± 0.24 0.914
HS-CRP at 48 h 5.11 ± 8.79
a 4.87 ± 7.24
a 0.99 ± 1.11
b < 0.001
BMI (kg/m
2) 25.2 ± 3.5 24.3 ± 3.9 24.7 ± 3.1 0.254
HbA1C level, % 6.90 ± 1.84 6.73 ± 1.85 - 0.565
SBP (mm Hg) 144 ± 20
a 143 ± 21
a 136 ± 18
b 0.024
DBP (mm Hg) 85 ± 12
a 83 ± 11
a 80 ± 11
b 0.041
Significant ECCA stenosis, % (n) 25% (20) 17.5% (14) - 0.246
Statin therapy 42.5% (34) 45% (36) - 0.750
ACEI/ARB therapy 41.3% (33) 38.8% (31) - 0.747
EPO therapy-related adverse events
Allergy 0% (0) - - -
Polycythemia 0% (0) - - -
Thrombosis event 0% (0) - - -
HS-CRP at day 21 2.95 ± 4.35 2.78 ± 2.95 - 0.991
*: by t-test or Chi-square test (between the two groups) or repeated measure of NOVA (among the three groups).
Letters (
a, b) indicate significant difference (at 0.05 level) by Bonferroni multiple comparison procedure. Same letter (
a, a) in two groups indicate no significant
difference (p > 0.05 level).
†: group 1 = with EPO treatment; group 2 = without EPO treatment.
Data are expressed as mean ± SD or % (No.) of patients.
ACEI/ARB = angiotensin converting enzyme inhibitor/angiotensin II type I receptor blocker; BMI = body mass index; DBP = diastolic blood pressure; ECCA = extra-
cranial carotid artery; EPC = endothelial progenitor cell; EPO = erythropoietin; HbA1C = hemoglobin A1C; HDL = high-density lipoprotein; LDL = low-density
lipoprotein; MRI = magnetic resonance imaging; SBP = systolic blood pressure; RBC = red blood pressure; WBC = white blood cell.
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MANE. Additionally, serum levels of total cholesterol
and LDL were significantly associated with 90-day
M A N E .F u r t h e r m o r e ,s e r u ml e v e lo fh s - C R Pa td a y2 1
was also strongly correlated with 90-day MANE. Con-
versely, EPO therapy was strongly and inversely predic-
tive of 90-day MANE. Finally, both systolic and diastolic
blood pressures were significantly related to 90-day
MANE. Further analysis revealed that SBP ≥ 135 mm
Hg and ≤ 150 mm Hg were significantly associated with
a favorable 90-day clinical outcome (p < 0.05).
The statistically significant predictors which were
shown in Table 3 were further utilized for the multiple
stepwise logistic regression analysis and the results
revealed that the serum level of hs-CRP level at both 48
h and day 21 after acute IS were significantly and inde-
pendently predictive of 90-day MANE. In addition, the
serum level of LDL was strongly and independently pre-
dictive of 90-day MANE. On the other hand, EPO ther-
apy and systolic blood pressure were significantly and
independently predictive of freedom from 90-day
MANE.
Correlation between Serum Level of hs-CRP and
Neurological Status (Figures 1, 2, 3 and 4)
The ROC curve analysis (Figure 1) revealed that serum
level of hs-CRP ≥ 2.985 mg/L at 48 h after acute IS was
the most powerful predictor of 90-day MANE with a
sensitivity of 76.8%, a specificity of 82.7%. The positive
predictive value was 61.4% and the negative predictive
value was 90.5%.
Assessment of the correlation between hs-CRP level
and degree of neurological impairment demonstrated
good correlations between serum level of hs-CRP and
NIHSS, Barthel Index, as well as modified Rankin Scale
score at 48 h after acute IS (Figure 2, 3 &4). Besides,
there was a fairly good correlation between 21-day
serum level of hs-CRP and 90-day NIHSS (Figure 5).
Discussion
This study, which compared the role of serum hs-CRP
level during acute phase (at 48 hour) with that during
convalescent phase (day 21) in predicting 90-day clinical
outcome of patients after acute IS with or without EPO
therapy, yielded several striking implications. First, hs-
CRP levels during both acute and convalescent phases
were remarkably higher in IS patients than in healthy
control subjects. Second, EPO therapy did not signifi-
cantly alter the serum level of hs-CRP. Third, hs-CRP
levels during both acute phase and convalescent phase
of IS were significantly and independently predictive of
90-day MANE. In contrast, EPO therapy was signifi-
cantly and independently predictive of freedom from
90-day MANE.
Inflammatory Reaction in Patients after Acute Ischemic
Stroke
Consistent with the results of other recent studies
[13,14], our findings also demonstrated hs-CRP level, a
new pro-inflammatory index, were substantially
increased in patients with IS upon admission. This find-
ing implicated that patients with acute IS are in an
inflammatory situation. Of importance is that the hs-
CRP level on day 21 after acute IS, a time point when
this biomarker is supposed to return to its baseline
Table 2 Comparisons of Neurological Status and Clinical
Outcome between IS Patients with and without EPO
Treatment
Variables Group 1†
(n = 80)
Group 2†
(n = 80)
P value
NIHSS at 48 h 6.69 ± 4.58 7.30 ± 7.58 0.537
Modified Rankin Scale score at 48 h 3.61 ± 1.42 2.83 ± 1.63 0.109
Barthel Index at 48 h 55.9 ± 31.0 60.6 ± 36.2 0.378
NIHSS on day 90 4.26 ± 5.41 5.53 ± 7.91 0.240
Recurrent stroke, % (n) 0% (0) 8.8% (7) 0.007
90-day mortality, % (n) 2.5% (2) 1.3% (1) 0.560
NIHSS ≥ 8.0 13.8% (11) 28.8% (23) 0.034
Combined MANE, % (n) 16.3% (13) 36.3% (29) 0.007
†: group 1 = with EPO treatment; group 2 = without EPO treatment.
IS = ischemic stroke; MANE = major adverse neurological event (defined as
NIHSS ≥ 8, recurrent stroke or death on day 90 after acute IS); NIHSS =
national institutes of health stroke scale.
Table 3 Univariate Analysis of Predictors for Combined
MANE on Day 90 after Ischemic Stroke
Variables Odds Ratio 95% CI p value
Systolic blood pressure 0.981 0.963 - 0.999 0.047
Diastolic blood pressure 0.965 0.934 - 0.998 0.035
Total cholesterol level 1.011 1.022-1.02 0.015
Low-density lipoprotein 1.011 1.001 - 1.022 0.03
EPO therapy 0.341 0.161 - 0.72 0.005
HS-CRP at 48 h 1.086 1.036 - 1.140 0.001
HS-CRP at day 21 1.138 1.031-1.256 0.01
CI = confidence interval; EPO = Erythropoietin; MANE = major adverse
neurological event.
Table 4 Multiple Stepwise Logistic Regression Analysis of
Predictors for Combined MANE on Day 90 after Ischemic
Stroke
Variables Odds Ratio 95% CI p value
Low-density lipoprotein 1.022 1.008 - 1.036 0.001
Systolic blood pressure 0.969 0.946 - 0.993 0.012
HS-CRP at 48 h 1.069 1.011 - 1.131 0.018
HS-CRP at day 21 1.163 1.021-1.324 0.023
EPO therapy 0.334 0.153 - 0.730 0.006
CI = confidence interval; EPO = erythropoietin; MANE = major adverse
neurological event.
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study patients than in healthy control subjects. This
f i n d i n gs u g g e s t st h a tc h r o n i ca n dp e r s i s t e n ti n f l a m m a -
tion may occur in patients even prior to acute IS.
Previous studies have already shown that an elevated
serum CRP level reflects an increased tendency for pla-
que rupture and a high atherosclerotic burden [4,6,7,29].
Additionally, oxidized LDL [30], which has been shown
Figure 1 Receiver operating characteristics (ROC) curve analysis revealed that the serum level of CRP ≥ 2.985 mg/L at 48 h after acute
IS was the most powerful predictor of 90-day MANE with a sensitivity of 76.8%, a specificity of 82.7%, p < 0.001.
Figure 2 Spearman’s rank test for the correlation between serum level of high-sensitivity C-reactive protein (hs-CRP) and National
Institutes Health Stroke Scale (NIHSS) at 48 h after acute ischemic stroke (p < 0.001; r = 0.467).
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dysfunction and free radical generation, was found be an
independent predictor of 90-MANE. The results of the
present study and those from others [4,6,7,29,30], there-
fore, support the proposal that acute IS may be resulted
from acute plaque rupture as a consequence of chronic
inflammatory process.
Level and Value of Serum hs-CRP in Patients after Acute
Ischemic Stroke
The association between increased circulating level of
hs-CRP and unfavorable short-term [14,15] and long-
term [31-33] outcomes have been previously extensively
investigated. Additionally, one [34] of these previous
studies [14,15,31-33] has evaluated the serial changes of
Figure 3 Spearman’s rank test for the correlation between serum level of hs-CRP and modified Ranking Stroke Scale (RSS) at 48 h
after acute ischemic stroke (p < 0.001; r = 0.430).
Figure 4 Spearman’s rank test for the correlation between serum level of hs-CRP and Barthel index at 48 h after acute ischemic
stroke (p < 0.001; r = -0.459).
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h and 48 h after symptom onset) of IS and showed that
the circulating level of hs-CRP at 48 h after acute IS
was the most predictor of unfavorable long-term clinical
outcome. In the present study we also found that circu-
lating level of hs-CRP at 48 h was better than the level
of this biomarker at day 21 after acute IS for predictive
of 90-day MANE. Therefore, our finding reinforced the
finding of previous study [34].
Interestingly, although the level of hs-CRP during
acute phase of IS has been shown to be significantly
predictive of the severity of stoke and prognostic out-
come [14,15,31,32], the value of hs-CRP level at conva-
lescent stage of IS in predicting clinical outcome has
not been addressed. The novel finding in the present
was that circulating level of hs-CRP at day 21 after
acute IS remained significantly and independently pre-
dictive of 90-day MANE. Therefore, our finding
extended the finding of previous studies [14,15,31-35].
The importance of the current study is that hs-CRP
levels were obtained from the same group of study
patients during both acute and convalescent phases for
determining the association of this biomarker with clini-
cal outcome. In addition, another important finding is
that hs-CRP level at 48 h after IS was significantly and
strongly correlated with NIHSS, Barthel Index, and
modified Rankin Scale score. Above all, the most impor-
tant finding is that hs-CRP levels during both acute and
convalescent phases were significantly and
independently predictive of 90-day MANE. Our findings,
therefore, support the validity of using serum hs-CRP
level in predicting clinical outcome in patients with and
without IS regardless of the timing for blood sampling
[9,11,15,15,31-33].
Impact of EPO Therapy on Serum hs-CRP Level and 90-
day MANE
Some clinical observational studies [36,37] have shown
that EPO therapy improved the clinical outcome of
patients after acute IS. The essential finding in the pre-
sent study is that EPO therapy was an independent pre-
dictor of improvement in 90-day MANE. Therefore, our
findings, in addition to strengthening those of previous
studies [36,37], highlight the therapeutic potential of
EPO in patients after IS who are not suitable candidates
for thrombolytic therapy.
The baseline variables (Table 1) were identical in
group 1 and group 2 patients upon presentation, there-
fore, it is not surprising that the circulating level of hs-
CRP did not differ between group 1 and 2 at 48 hour
after acute IS. Surprisingly, while EPO has been reported
to be anti-inflammatory [19,20,38] and hs-CRP has been
widely accepted as an important inflammatory biomar-
ker for predicting prognostic outcome of cardiovascular
and cerebrovascular diseases [4,6,7,9-11,14,15,31,32],
serum hs-CRP levels at day 21 after IS did not differ
between the patients with and those without EPO ther-
apy. However, the results of the present study identified
Figure 5 Spearman’s rank test for the correlation between 21 -day serum level of high-sensitivity C-reactive protein (hs-CRP) and
National Institutes Health Stroke Scale (NIHSS) at 90-day after acute ischemic stroke (p = 0.003; r = 0.247).
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from 90-MANE. This finding supports the mechanisms
underlying the improvement in clinical outcome after
EPO therapy against acute IS through enhancing circu-
lating level of EPCs [24] rather than via inhibiting
inflammatory response.
Blood Pressure upon Admission Independently Predictive
of 90-Day MANE
The association between blood pressure and clinical
outcome after acute IS has been extensively investigated
in previous studies [39-41]. Control of systolic blood
pressure to an optimal level around 140-150 mm Hg
has been shown to improve clinical outcome after acute
IS [40]. In the present study, the mean systolic blood
pressure of our patients was 140 mmHg. Further analy-
sis revealed that SBP ≥ 135 mm Hg and ≤ 150 mm Hg
was significantly associated with a favorable 90-day clini-
cal outcome. Also of importance in the current study is
that systolic blood pressure was found to be indepen-
dently predictive of freedom from 90-day MANE.
Therefore, our findings were consistent with those of
previous studies [39-41].
Study Limitation
First, this study only chose two time points rather than
constant blood samplings during the whole time course
to determine the changes in serum level of hs-CRP in
patients after acute IS. Therefore, we did not provide
information on the serial changes in circulating hs-CRP
level after IS. Second, although this study did not show
significant reduction in serum hs-CRP level following a
standard EPO dosage, whether a higher dose of EPO
would actually reduce the serum level of hs-CRP in the
setting of acute IS remains unclear.
Conclusion
Serum level of hs-CRP during both acute and convales-
cent phases was significantly and independently predic-
tive of 90-day MANE, whereas EPO therapy was
significantly and independently predictive of freedom
from 90-day MANE. However, EPO treatment did not
diminish the predictive value of hs-CRP for unfavorable
clinical outcome after acute IS.
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